secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2024-08-02T23:59:59+00:00
Accession:  0001867096-24-000137
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma promotes Kevin McCulloch to President and COO
-------------------------------------------------------------

- Kevin McCulloch, former Chief Commercial Officer, was promoted to President and COO effective August 1, 2024.
- McCulloch will receive an annual base salary of $520,000 and a target annual incentive of 50% of base salary.
- He was granted 150,000 restricted stock units vesting over 3 years and 200,000 stock appreciation rights vesting at 2 years.
- Severance includes 1.25x salary plus target incentive if terminated without cause, or 1.5x if within 12 months after a change in control.
- McCulloch reports to CEO John Shannon and joined Xeris in 2018 as SVP of Global Operations and Business Development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709624000137/0001867096-24-000137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709624000137/xers-20240801.htm
  HTML page:      https://secwatch.observer/filing/0001867096-24-000137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer